Phase 3 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Jiangsu HengRui Medicine Co., Ltd.206 enrolled1 locationNCT07241416
Recruiting
Phase 3
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Karolinska Institutet750 enrolled32 locationsNCT03903835
Recruiting
Phase 3
Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
The First Affiliated Hospital with Nanjing Medical University100 enrolled1 locationNCT05956639